Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.
Campiglio M, Bufalino R, Sandri M, Ferri E, Aiello RA, De Matteis A, Mottolese M, De Placido S, Querzoli P, Jirillo A, Bottini A, Fantini M, Bonetti A, Pedani F, Mauri M, Molino A, Ferro A, Pupa SM, Sasso M, Ménard S, Balsari A, Tagliabue E. Campiglio M, et al. Breast Cancer Res Treat. 2011 Jul;128(1):147-54. doi: 10.1007/s10549-011-1484-4. Epub 2011 Apr 11. Breast Cancer Res Treat. 2011. PMID: 21479926 Clinical Trial.
HER2 as a target for breast cancer therapy.
Tagliabue E, Balsari A, Campiglio M, Pupa SM. Tagliabue E, et al. Among authors: campiglio m. Expert Opin Biol Ther. 2010 May;10(5):711-24. doi: 10.1517/14712591003689972. Expert Opin Biol Ther. 2010. PMID: 20214497 Review.
The HER2 World: Better Treatment Selection for Better Outcome.
Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S. Tagliabue E, et al. Among authors: campiglio m. J Natl Cancer Inst Monogr. 2011;2011(43):82-5. doi: 10.1093/jncimonographs/lgr041. J Natl Cancer Inst Monogr. 2011. PMID: 22043048
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.
Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini PL, Triulzi T, Menard S, Nanni P, Tagliabue E, Pupa SM. Castagnoli L, et al. Among authors: campiglio m. Cancer Res. 2014 Nov 1;74(21):6248-59. doi: 10.1158/0008-5472.CAN-14-0983. Epub 2014 Aug 27. Cancer Res. 2014. PMID: 25164009
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.
Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E. Triulzi T, et al. Among authors: campiglio m. Oncotarget. 2015 Sep 29;6(29):28173-82. doi: 10.18632/oncotarget.4405. Oncotarget. 2015. PMID: 26334217 Free PMC article.
Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study.
Campiglio M, Bufalino R, Sasso M, Ferri E, Casalini P, Adamo V, Fabi A, Aiello R, Riccardi F, Valle E, Scotti V, Tabaro G, Giuffrida D, Tarenzi E, Bologna A, Mustacchi G, Bianchi F, Balsari A, Ménard S, Tagliabue E. Campiglio M, et al. Breast Cancer Res Treat. 2013 Aug;141(1):101-10. doi: 10.1007/s10549-013-2658-z. Epub 2013 Aug 13. Breast Cancer Res Treat. 2013. PMID: 23942848 Free PMC article.
Role of HER2 in wound-induced breast carcinoma proliferation.
Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Ménard S. Tagliabue E, et al. Among authors: campiglio m. Lancet. 2003 Aug 16;362(9383):527-33. doi: 10.1016/S0140-6736(03)14112-8. Lancet. 2003. PMID: 12932384
93 results